Table 5.

Cumulative incidence of medium-term adverse events.

	Cumulative incidence [95% CI] of grade ≥ 2 adverse events after IMRT
	At 13 months*	At 26 months*
Esophageal adverse events	–	–
Skin adverse events	1.1% [0.4–3.5]	1.7% [0.6–4.5]
Fibrosis, total mastectomy	4.5% [1.9–10.5]	7.0% [2.9–16.4]
Fibrosis, partial mastectomy	5.2% [2.6–10.2]	7.3% [3.5–15.1]
Scar fibrosis, total mastectomy	5.5% [2.5–11.9]	5.5% [2.5–11.9]
Scar fibrosis, partial mastectomy	5.7% [3.0–10.6]	7.8% [3.9–15.6]

*The cumulative incidences are quoted at 13 and 26 months (rather than 12 and 24 months) so as not to underestimate the values, since the annual check-ups often took place slightly later than 12 and 24 months. Skin adverse events were defined as radiodermatitis, ulceration-necrosis, telangiectasia, atrophy, hyperpigmentation or hypopigmentation. With regard to surgical bed fibrosis, only fibrosis absent or of a higher grade on inclusion were considered.